Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15449851 | 1.00 | KDM4E (0.42) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL15449852 | 1.00 | KDM4E (0.42) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL20608080 | 0.92 | USP30 (0.45) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL20342532 | 0.87 | GPR119 (0.36) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL3496830 | 0.85 | MAPT (0.39) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL25197591 | 0.83 | DDB1 (0.42) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL15437616 | 0.83 | DDB1 (0.42) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL16122116 | 0.83 | KDM4E (0.43) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL21565384 | 0.81 | DDB1 (0.41) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL24850970 | 0.81 | DDB1 (0.41) | KDM4EMAPTTHRBDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169673-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3169672-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10208064-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. | 2019-02-19 | — | — | US | disclosed |
| EP-2968288-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9926317-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP DOHME CORP. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170275298-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170275298-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2014150132-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150132-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014015495-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018764-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275298-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KDM4E 2264/4885MAPT 4195/4885THRB 784/4885 |
| US-10208064-B2 | Inhibitors of the renal outer medullary potassium channel | KCNJ11, KCNJ1, KCNJ2 | KDM4E 2184/4885MAPT 4209/4885THRB 754/4885 |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KDM4E 2511/4885MAPT 4223/4885THRB 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.